Prosecution Insights
Last updated: October 17, 2026
Application No. 18/949,084

THERAPEUTIC COMPOUNDS

Non-Final OA §112
Filed
Nov 15, 2024
Priority
Nov 17, 2023 — EU 23210687.2
Examiner
SHAMEEM, GOLAM M
Art Unit
1621
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Sanofi S.A.
OA Round
1 (Non-Final)
87%
Grant Probability
Favorable
1-2
OA Rounds
0m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 87% — above average
87%
Career Allowance Rate
777 granted / 896 resolved
+26.7% vs TC avg
Strong +16% interview lift
Without
With
+15.9%
Interview Lift
resolved cases with interview
Fast prosecutor
1y 10m
Avg Prosecution
37 currently pending
Career history
922
Total Applications
across all art units

Statute-Specific Performance

§101
2.8%
-37.2% vs TC avg
§103
5.1%
-34.9% vs TC avg
§102
18.0%
-22.0% vs TC avg
§112
23.6%
-16.4% vs TC avg
Black line = Tech Center average estimate • Based on career data from 896 resolved cases

Office Action

§112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION Priority This application claims benefit for foreign priority under 35 U.S.C. § 119(a)-(d) to EPO PNG media_image1.png 18 166 media_image1.png Greyscale , is acknowledged. Status of Claims Claims 1-30 and 33 are currently pending in the application. Claims 31-32 were canceled. Information Disclosure Statement Receipt is acknowledged of Information Disclosure Statement (IDS), filed on 01/16/2025, which has been entered in the file. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claim 33 (currently amended) is rejected under 35 U.S.C. § 112 (b) or 35 U.S.C. § 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor, or for pre-AIA the Applicant regards as the invention. The expressions “such as” [claim 33 (currently amended), line 3, page 30 and all other occurrences, if any] and “in particular” [claim 33 (currently amended), line 4, page 30 and all other occurrences, if any], render the claim indefinite because it is unclear whether the limitation following the phrase is part of the claimed invention. See MPEP § 2173.05 (d) and therefore, it is not possible to ascertain the metes and bounds of the claimed subject matter. The use of expressions “such as” and “in particular” in the middle of the claim also may lead to confusion over the intended scope of the claim. It is suggested that the expressions “such as” and “in particular” be deleted or amend the claim within the context and scope of the claim in order to overcome the rejection. Telephone Inquiry Any inquiry concerning this communication or earlier communications from the examiner should be directed to Golam Shameem, Ph.D. whose telephone number is (571) 272-0706. The examiner can normally be reached on Monday-Thursday from 7:30 AM - 6:00 PM. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Clinton Brooks, Ph.D. can be reached at (571) 270-7682. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://portal.uspto.gov/external/portal. Should you have questions about access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist, whose telephone number is (571) 272-1600. /GOLAM M SHAMEEM/Primary Examiner, Art Unit 1621
Read full office action

Prosecution Timeline

Nov 15, 2024
Application Filed
Aug 18, 2026
Non-Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12753171
5-MEMBERED HETEROARYLAMINOSULFONAMIDES FOR TREATING CONDITIONS MEDIATED BY DEFICIENT CFTR ACTIVITY
4y 4m to grant Granted Oct 06, 2026
Patent 12753186
NOVEL COMPOUND AND COMPOSITION FOR PREVENTING OR TREATING NEUROINFLAMMATORY BRAIN DISEASES COMPRISING SAME AS ACTIVE INGREDIENT
2y 5m to grant Granted Oct 06, 2026
Patent 12747232
COMPOUNDS, COMPOSITIONS, AND METHODS
2y 3m to grant Granted Sep 29, 2026
Patent 12741944
INHIBITORS OF SPINSTER HOMOLOG 2 (SPNS2) FOR USE IN THERAPY
3y 6m to grant Granted Sep 22, 2026
Patent 12741953
PHTHALAZINONE COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF
3y 9m to grant Granted Sep 22, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
87%
Grant Probability
99%
With Interview (+15.9%)
1y 10m (~0m remaining)
Median Time to Grant
Low
PTA Risk
Based on 896 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month